BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BA, Friedman LS. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999;25:91-6. [PMID: 10337991 DOI: 10.1002/(sici)1098-2264(199906)25:2<91::aid-gcc3>3.0.co;2-5] [Cited by in Crossref: 56] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma. Cell Cycle. 2012;11:4152-4166. [PMID: 23047606 DOI: 10.4161/cc.22226] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
2 McKeon F. Killing the umpire: cooperative defects in mitotic checkpoint and BRCA2 genes on the road to transformation. Breast Cancer Res 1999;1:8-10. [PMID: 11250674 DOI: 10.1186/bcr4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
3 Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12:68-78. [PMID: 22193408 DOI: 10.1038/nrc3181] [Cited by in Crossref: 703] [Cited by in F6Publishing: 662] [Article Influence: 63.9] [Reference Citation Analysis]
4 McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513-527. [PMID: 28835720 DOI: 10.1038/nrc.2017.60] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 23.0] [Reference Citation Analysis]
5 Feng W, Jasin M. Homologous Recombination and Replication Fork Protection: BRCA2 and More! Cold Spring Harb Symp Quant Biol 2017;82:329-38. [PMID: 29686033 DOI: 10.1101/sqb.2017.82.035006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
6 Mensah L, Ferguson JL, Shive HR. Genotypic and Phenotypic Variables Affect Meiotic Cell Cycle Progression, Tumor Ploidy, and Cancer-Associated Mortality in a brca2-Mutant Zebrafish Model. J Oncol 2019;2019:9218251. [PMID: 30930946 DOI: 10.1155/2019/9218251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Houle CD, Peddada SD, McAllister KA, Ward T, Malphurs J, Gersch WD, Davis BJ. Mutant Brca2/p53 mice exhibit altered radiation responses in the developing mammary gland. Exp Toxicol Pathol 2005;57:105-15. [PMID: 16325521 DOI: 10.1016/j.etp.2005.06.001] [Reference Citation Analysis]
8 Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol 2015;172:1498-506. [PMID: 25524463 DOI: 10.1111/bjd.13626] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
9 Shive HR, West RR, Embree LJ, Golden CD, Hickstein DD. BRCA2 and TP53 collaborate in tumorigenesis in zebrafish. PLoS One 2014;9:e87177. [PMID: 24489863 DOI: 10.1371/journal.pone.0087177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
10 Jeong JH, Jo A, Park P, Lee H, Lee HO. Brca2 deficiency leads to T cell loss and immune dysfunction. Mol Cells 2015;38:251-8. [PMID: 25666348 DOI: 10.14348/molcells.2015.2302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 2006;6:80. [PMID: 16563154 DOI: 10.1186/1471-2407-6-80] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
12 Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 2009;4:e8404. [PMID: 20046879 DOI: 10.1371/journal.pone.0008404] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ezzati M, Abdullah A, Shariftabrizi A, Hou J, Kopf M, Stedman JK, Samuelson R, Shahabi S. Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices 2014;2014:953509. [PMID: 27382614 DOI: 10.1155/2014/953509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
14 Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009;8:48. [PMID: 19602291 DOI: 10.1186/1476-4598-8-48] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
15 Rajagopalan S, Andreeva A, Rutherford TJ, Fersht AR. Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. Proc Natl Acad Sci U S A 2010;107:8587-92. [PMID: 20421506 DOI: 10.1073/pnas.1003689107] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
16 Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, Aaronson SA, Lee SW. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol. 2000;20:7450-7459. [PMID: 11003642 DOI: 10.1128/MCB.20.20.7450-7459.2000] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
17 Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival. BMC Cancer 2005;5:134. [PMID: 16229746 DOI: 10.1186/1471-2407-5-134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
18 Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006;66:8949-53. [PMID: 16982732 DOI: 10.1158/0008-5472.CAN-06-1495] [Cited by in Crossref: 81] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
19 Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 2009;4:e8534. [PMID: 20046869 DOI: 10.1371/journal.pone.0008534] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
20 Wilkins JF, Cannataro VL, Shuch B, Townsend JP. Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget 2018;9:22243-53. [PMID: 29854275 DOI: 10.18632/oncotarget.25155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Kim KY, Park DW, Jeung EB, Choi KC. Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis? J Vet Sci 2010;11:291-7. [PMID: 21113097 DOI: 10.4142/jvs.2010.11.4.291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Pan Z, Xie X. BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget 2017;8:97657-70. [PMID: 29228641 DOI: 10.18632/oncotarget.18280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
23 Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001;3:27-32. [PMID: 11123866 DOI: 10.1007/s11912-001-0039-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
24 Zhang J. The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci 2013;3:11. [PMID: 23388117 DOI: 10.1186/2045-3701-3-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
25 Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 2013;3:113. [PMID: 23675572 DOI: 10.3389/fonc.2013.00113] [Cited by in Crossref: 136] [Cited by in F6Publishing: 135] [Article Influence: 15.1] [Reference Citation Analysis]